Eltanexor and Venetoclax
Phase Ib Study of Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 60 patients (estimated)
- Sponsors
- Vanderbilt-Ingram Cancer Center
- Collaborators
- Karyopharm Therapeutics, National Cancer Institute (NCI)
- Tags
- Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1913
- NCT Identifier
- NCT06399640
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.